- Stocks
- Healthcare
- NASDAQ: CMRX

Price (delayed)

$1.28

Market cap

$112.99M

P/E Ratio

0.65

Dividend/share

N/A

EPS

$1.97

Enterprise value

$88.97M

Chimerix is a development-stage biopharmaceutical company dedicated to accelerating the advancement of innovative medicines that make a meaningful impact in the lives of patients living with cancer and other serious

The net income has soared by 199% YoY and by 12% from the previous quarter

The EPS has soared by 197% YoY and by 13% from the previous quarter

CMRX's quick ratio is down by 34% since the previous quarter

The equity has declined by 6% since the previous quarter

What are the main financial stats of CMRX

Market
Valuations
Earnings

Shares outstanding

88.27M

Market cap

$112.99M

Enterprise value

$88.97M

Price to earnings (P/E)

0.65

Price to book (P/B)

0.44

Price to sales (P/S)

3.31

EV/EBIT

0.52

EV/EBITDA

0.52

EV/Sales

2.63

Revenue

$33.82M

EBIT

$172.2M

EBITDA

$172.31M

Free cash flow

-$46.94M

Per share
Balance sheet
Liquidity

EPS

$1.97

Free cash flow per share

-$0.54

Book value per share

$2.92

Revenue per share

$0.39

TBVPS

$3.19

Total assets

$279.34M

Total liabilities

$22.48M

Debt

$1.82M

Equity

$256.86M

Working capital

$207.72M

Debt to equity

0.01

Current ratio

11.18

Quick ratio

10.7

Net debt/EBITDA

-0.14

Margins
Efficiency
Dividend

EBITDA margin

509.4%

Gross margin

98.7%

Net margin

509%

Operating margin

-178.5%

Return on assets

99.5%

Return on equity

113.5%

Return on invested capital

261.2%

Return on capital employed

66.5%

Return on sales

509.1%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Chimerix stock price performed over time

Intraday

-4.48%

1 week

-5.88%

1 month

-22.42%

1 year

-75.05%

YTD

-31.18%

QTD

-31.18%

How have Chimerix's revenue and profit performed over time

Revenue

$33.82M

Gross profit

$33.38M

Operating income

-$60.39M

Net income

$172.17M

Gross margin

98.7%

Net margin

509%

The net income has soared by 199% YoY and by 12% from the previous quarter

The net margin has soared by 106% YoY and by 10% from the previous quarter

The company's operating margin has surged by 98% YoY and by 22% QoQ

The operating income has soared by 65% YoY and by 21% QoQ

What is Chimerix's growth rate over time

What is Chimerix stock price valuation

P/E

0.65

P/B

0.44

P/S

3.31

EV/EBIT

0.52

EV/EBITDA

0.52

EV/Sales

2.63

The EPS has soared by 197% YoY and by 13% from the previous quarter

The stock's price to book (P/B) is 89% less than its last 4 quarters average of 4.0 and 85% less than its 5-year quarterly average of 2.9

The equity has declined by 6% since the previous quarter

CMRX's P/S is 99% lower than its last 4 quarters average of 255.6 and 97% lower than its 5-year quarterly average of 104.3

Chimerix's revenue has increased by 2.3% from the previous quarter

How efficient is Chimerix business performance

CMRX's return on assets has surged by 177% year-on-year but it is down by 17% since the previous quarter

Chimerix's return on equity has surged by 170% YoY but it has decreased by 23% QoQ

The ROS has soared by 106% YoY and by 9% from the previous quarter

Chimerix's ROIC has plunged by 57% from the previous quarter

What is CMRX's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for CMRX.

How did Chimerix financials performed over time

The total assets has soared by 178% YoY but it has contracted by 4.9% from the previous quarter

CMRX's quick ratio is down by 34% since the previous quarter

The debt is 99% less than the equity

The debt to equity has shrunk by 96% YoY

The debt has plunged by 89% YoY and by 8% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.